Dopamine dysregulation syndrome and levodopa-induced dyskinesias in parkinson disease: Common consequences of anomalous forms of neural plasticity

Clinical Neuropharmacology

Volumn 32, Issue 1, 2009, Pages 22-27

  Linazasoro, Gurutz ^a,b  

^a Centro de Investigacion Parkinson   (Spain)

^b Centro de Investigacion Parkinson   (Spain)

Author keywords

Addiction; Dyskinesias; Levodopa; Parkinson disease

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PREPRODYNORPHIN; PREPROENDOTHELIN;

CLINICAL FEATURE; DISEASE PREDISPOSITION; DOPAMINE DYSREGULATION SYNDROME; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG HALF LIFE; DYSKINESIA; HUMAN; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; BASAL GANGLIA; BEHAVIOR, ADDICTIVE; CEREBRAL CORTEX; DOPAMINE; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; NEURAL PATHWAYS; NEURONAL PLASTICITY; PARKINSON DISEASE;

EID: 67749116335     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181634ea6     Document Type: Review

References (62)

1. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595-604.
2. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004;17:393-398.
3. Linazasoro G, Van Blercom N, Lasa A. Hipótesis: enfermedad de Parkinson, síndrome de deficiencia de recompensa y efectos adictivos de levodopa. Neurologia 2004;19:356-378.
4. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioural disorders. Prog Brain Res 2000;126:325-341.
5. De la Fuente R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurol 2002;1:85-91.
6. Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570-1574.
7. Nader MA, Morgan D, Gage HD, et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci 2006;9:1050-1056.
8. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993;14:169-177.
9. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997;17:162-174.
10. 3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007;315:1267-1271.
11. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995;52:1183-1190.
12. 11C raclopride. Mov Disord 1997;12:33-38.
13. Linazasoro G, Obeso JA, Gómez JC, et al. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. Clin Neuropharmacol 1999:22:277-281.
14. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007;64:212-216.
15. Obeso JA, Linazasoro G, Gorospe A, et al. Complications associated with chronic levodopa therapy in Parkinson's disease. In: Olanow CW, Obeso JA, eds. Beyond the Decade of the Brain. Vol 2. Kent Wells Medical Ltd;1997:11-36.
16. Linazasoro G, Antonini A, Maguire RP, et al. Pharmacological and PET studies in patients with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. J Neural Transm 2004;111:497-509.
17. De la Fuente Fernández R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
18. Sossi V, de la Fuente-Fernández R, Schulzer M, et al. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006;129:1050-1058.
19. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-858.
20. Mitchell IJ, Clarke CE, Boyce S, et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 1989;32:213-226.
21. Mitchell IJ, Boyce S, Sambrook MA, et al. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992;115:809-824.
22. Guigoni C, Li Q, Aubert I, et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine - induced dyskinesia. J Neurosci 2005;25:2102-2107.
23. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005;8:1445-1449.
24. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000;23:S71-S77.
25. Gerdeman GL, Partridge JG, Lupica CR, et al. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci 2003;26:184-192.
26. Linazasoro G. New ideas on the pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: age, genes and neural plasticity. Trends Pharmacol Sci 2005;26:391-397.
27. Pisani A, Centonze D, Bernardi G, et al. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 2005;20:395-402.
28. Linazasoro G. Plasticity in Parkinson's disease: from compensatory usefulness to negative aberrant behaviours. Focus Parkinson's Dis 2006;18:5-9.
29. Calabresi P, Giacomini P, Centonze D, et al. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000;47:S60-S68.
30. Cooke SF, Bliss TVP. Plasticity in the human central nervous system. Brain 2006;129:1659-1670.
31. Bear MF, Malenka RC. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol 1994;4:389-399.
32. Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001;294:1030-1038.
33. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron 2004;44:5-21.
34. Quartarone A, Siebner HR, Rothwell JC. Task-specific hand dystonia: can too much plasticity be bad for you? Trends Neurosci 2006;29:193-200.
35. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-dopa - induced dyskinesia. Nat Neurosci 2003;6:501-505.
36. Dunnet S. L-Dopa, dyskinesia and striatal plasticity. Nat Neurosci 2003;6:437-438.
37. Jones S, Bonci A. Synaptic plasticity and drug addiction. Curr Opin Pharmacol 2005;5:20-25.
38. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 2006;30:215-238.
39. Carlezon WA, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci 2005;28:436-446.
40. Andersson M, Westin JE, Cenci MA. Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J Neurosci 2003;17:661-666.
41. Funkiewicz A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003;18:524-530.
42. Yin HH, Knowlton BJ. The role of basal ganglia in habit formation. Nat Neurosci Rev 2006;7:464-476.
43. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
44. Parkinson Study Group. Pramipexole vs levodopa as initial therapy for Parkinson's disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
45. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double blind levodopa controlled trial. Drugs 1998;55(suppl 1):23-40.
46. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
47. Stocchi F, Ruggieri S, Vacca L, et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125:2058-2066.
48. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-157.
49. Stocchi F, Vacca L, Ruggieri S, et al. Intermittent versus continuous administration of levodopa in advanced Parkinson's disease. A clinicopharmacological study. Arch Neurol 2005;62:905-910.
50. Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005;20:1052-1055.
51. Houeto JL, Mesnage V, Mallet L, et al. Behavioral disorders, Parkinson's disease and sub-thalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:701-707.
52. Smeding H, Goudriaan A, Foncke E, et al. Pathological gambling after bilateral STN stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007;78:517-519.
53. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21:1941-1946.
54. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000;15:869-872.
55. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-1381.
56. Carey RJ. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance. Brain Res 1991;568:205-214.
57. Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007;68:301-303.
58. Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007;22:1757-1763.
59. Hadj Tahar A, Gregoire L, Bangassoro Bedard PJ. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 2000;23:195-202.
60. Carlsson T, Winkler C, Burger C, et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-dopa delivery using rAAV vectors. Brain 2005;128:559-569.
61. Bejjani BP, Arnulf I, Demeret S, et al. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Ann Neurol 2000; 47:655-658.
62. Kuhar MJ. Social rank and vulnerability to drug abuse. Nat Neurosci 2002;5:88-90.